Your cancer,
your cells,
your treatment
Palitra helps cancer patients who want rigorous personalization before their next treatment decision by testing rational therapeutic options against their own tumor cells.
Using data to help clinicians choose better answers
Whether facing a rare cancer, an uncertain outlook, or having exhausted standard of care, we go beyond off-the-shelf recommendations through maximal testing of therapeutic options against your own tumor cells.
The result is an actionable, personalized decision tree built on direct evidence from your tumor's biology.
How we work with you
Mark Stevens is the founding CEO of Palitra, bringing expertise cultivated over 15 years of experience at the intersection of cancer biology, translational medicine, and precision diagnostics. He holds a PhD in Biology from MIT, where his doctoral research and work at Dana Farber Cancer Institute became the foundation for Travera, a functional diagnostics company he cofounded to measure how individual patients' tumors respond to drugs. At Palitra, he channels that background into helping individual cancer patients create and execute personalized, maximalist testing strategies that use direct evidence measured from their own cells.
